Premium Japanese Konnyaku Rice & Shirataki Noodle uses Konjac Glucomannan Hydrolysates (GMH) to Improve the Health of the Skin and Reduce Acne Vulgaris
-
Medical Office and Laser Clinic, Maryam Medical Complex, 20 Pars Ave., Shamsabadi Ave. Esfahan, Iran (Elaheh Bateni)
-
Glycologic Limited, 70 Cowcaddens Road, Glasgow G4 0BA, United Kingdom (Richard Tester, Farage Al-Ghazzewi, Kamran Alvani)
-
Samen Pharmacy, Amadegahave., Esfahan, Iran (Soheil Bateni)
-
Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Royal College, 204 George Street, Glasgow G1 1XW, United Kingdom
Abstract
Glucomannan hydrolysates (GMH) have been shown to have positive prebiotic properties and when ingested have been shown to have a positive but indirect impact on the skin. However, direct in vivo topical benefits have not been established. The aim of this work was to establish how effective GMH is with respect to improving skin health especially the reduction of infection due to acne vulgaris.
Twenty-six female volunteers aged between 18 to 39 years with active lesions of acne vulgaris were included in this study. Patients were assigned randomly into two groups to receive either a standard treatment or a spray formulation containing GMH at a concentration of 5% (w/v).
Before and during treatment, the skin was evaluated according to the acne severity index (ASI). The results showed that there was a significant (P< 0.001) improvement of the skin health at the second (20 days) and third clinical evaluation (40 days) for established (e.g. antibiotics) and GMH treatments. Overall these data indicate that the GMH could be used as a prophylactic or novel topical therapeutic product for acne vulgaris and to improve skin health more generally.
Keywords Acne Vulgaris, Lesions, Skin Health, Konjac Glucomannan, Topical Therapeutic
Click Here to join as member, and ask to receive this clinical report and scientific evidence in PDF format.
Premium Japanese Konnyaku Rice & Shirataki Noodle's beneficial effects of Viscous Dietary Fiber from Konjac Glucomannan in Subjects with the Insulin Resistance Syndrome
VLADIMIR VUKSAN, PHD EDWARD VIDGEN, BSC
JOHN L. SIEVENPIPER, BASCFURIO BRIGHENTI, PHD
ROBIN OWEN, RD, MSC ROBERT G. JOSSE, MBBS
JEFFERY A. SWILLEY, MD LAWRENCE A. LEITER, MD
PETER SPADAFORA, MD, MSC ZHENG XU, MD
DAVID J.A. JENKINS, MD, DSCRENATO NOVOKMET
F rom the Department of Nutritional Sciences (V. V., J.L.S., R.O., J.A.S., P.S., D.J.A.J., E.V., R.G.J., L.A.L., Z.X.,
R.N.), Clinical Nutrition and Risk Factor Modification Center, St. Michael’s Hospital, Faculty of Medicine, University
of To ronto, To ronto, Canada; and the Department of Nutrition (F.B.), University of Milan, Milan, Italy.
A d d ress correspondence and reprint requests to Vladimir Vuksan, PhD, Clinical Nutrition and Risk Factor
Modification Centre, St. Michael’s Hospital, 6138-61 Queen St. E., To ronto, Ontario, Canada M5C 2T2.
Results of a controlled metabolic trial
OBJECTIVE
Dietary fiber has recently received recognition for reducing the risk of developing diabetes and heart disease. The implication is that it may have therapeutic benefit in prediabetic metabolic conditions. To test this hypothesis, we investigated the effect of supplementing a high-carbohydrate diet with fiber from Konjac-mannan (KJM) on metabolic control in subjects with the insulin resistance syndrome .
RESEARCH DESIGN AND METHODS
We screened 278 free-living subjects between the ages of 45 and 65 years from the Canadian-Maltese Diabetes Study. A total of 11 (age 55 ± 4 years, BMI 28 ± 1.5 kg/m2) were recruited who satisfied the inclusion criteria: impaired glucose tolerance, reduced HDL cholesterol, elevated serum triglycerides, and moderate
hypertension. After an 8-week baseline, they were randomly assigned to take either KJM fiber–enriched test biscuits (0.5 g of glucomannan per 100 kcal of dietary intake or 8–13 g/day) or wheat bran fiber (WB) control biscuits for two 3-week treatment periods separated by a 2-week washout. The diets were isoenergetic, metabolically controlled, and conformed to National Cholesterol Education Program Step 2 guidelines. Serum lipids, glycemic control, and blood pressure were the outcome measures .
RESULTS
Decreases in serum cholesterol (total, 12.4 ± 3.1%, P 0.004; LDL, 22 ± 3.9%, P 0.002; total/HDL ratio, 15.2 ± 3.4%, ......
Click Here to join as member, and ask to receive this clinical results, conclusions and scientific evidence shown in the research design and methods in PDF format.
